Cardiac AI: Invest in Prevention, Not Promises

The venture capital game in healthcare AI is littered with the carcasses of failed companies next to a few massive winners. If you’re looking to put money into cardiovascular prevention AI, you have to be focused on capital efficiency and real clinical validation. You need to see a tool that plugs directly into how doctors and hospitals already work, not some vague promise about making the back office run better. The fact that Tiger Global backed both Viz.ai to a $1.2 billion valuation and Olive AI straight into a $900 million flaming wreck tells you everything you need to know.

The Contrasting Fates: Viz.ai’s Rise vs. Olive AI’s Collapse

Tracking who’s funding what, and for how much, is the fastest way to get a read on market validation. Just look at Tiger Global, a big name that managed to get on the right and wrong side of the same bet in healthcare AI. Their $100 million Series D into Viz.ai, which pushed its valuation up to $1.2 billion, was a smart play on clinically proven AI. Viz.ai does one thing very well: it uses AI to speed up stroke and cardiovascular disease detection, which has an immediate and obvious clinical benefit. On the other hand, Tiger Global’s heavy backing of Olive AI ended in a complete shutdown after the company incinerated about $900 million. Olive AI tried to do everything, promising to automate all sorts of administrative junk across the hospital, but it turned out to be a mess to implement, customers didn’t stick around, and it couldn’t prove a clear financial return for anyone. The lesson is brutally simple for investors. In healthcare, and especially for something as critical as heart disease, you get lasting funding by hitting hard clinical endpoints and showing you help patients, which is a much more compelling story than just making operations more efficient.

Clinical Validation as the Bedrock of Cardiovascular AI Investment

Data from the AI Health Investment Tracker is clear: companies that have published clinical studies and signed contracts with payers are the ones that survive and grow. This is especially true for cardiovascular AI, where you’re dealing with life-or-death situations and the impact on patients is deep. Investors are getting much tougher, looking past the marketing slides to the actual architecture of the AI and demanding a foundation of clinical evidence. Viz.ai is the perfect example. Its algorithms tear through medical images like CT scans to find and flag patients with a potential stroke, getting the alert to the right specialist in minutes. This isn’t a theoretical benefit. It’s a life-saving wedge product that fits right into an emergency department’s workflow and produces measurable improvements in how fast patients get treated. The value is simple: faster diagnosis means better outcomes for patients, which saves hospitals and payers money. That kind of clinical utility, especially when it comes with an FDA 510(k) clearance process, is what gets you adopted and paid. The vague admin automation that companies like Olive AI were selling just doesn’t have the same punch or provable ROI as an AI that demonstrably helps patients survive critical events.

The Power of Proprietary Data and Regulatory Acumen

Clinical results alone aren’t enough. The most investable companies in this space also have a “data moat” and really know their way around the FDA. Just look at Tempus AI. It’s a precision medicine company that GV backed, went public in June 2024, and now has an $11.18 billion market cap. While it’s mainly a cancer company, its playbook is the one to watch. Tempus built its business by collecting and crunching huge, complex sets of clinical and molecular data, creating a feedback loop that constantly improves its AI and makes it almost impossible for a competitor to catch up. For a cardiovascular AI startup, this means getting your hands on massive, high-quality datasets of ECGs, imaging, and patient outcomes. You have to prove your algorithm works reliably over time using Real-World Evidence (RWE), which is something the FDA guidance on Real-World Evidence is quite clear about. And working through the regulatory maze, getting a 510(k) or even a De Novo classification for a new device, and following GMLP (FDA/Health Canada/MHRA GMLP principles), is simply table stakes. The mature companies are the ones that build out their Quality Management Systems (QMS) to ISO 13485 standards from day one, because they know it saves them a world of regulatory pain down the road.

Payer Contracts and Reimbursement Pathways: The Commercial Imperative

In the end, your cool healthcare AI is worthless if no one will pay for it. To get durable funding and actually get used in hospitals, you have to show a clear path to getting reimbursed, which means getting payer contracts and CPT codes. A lot of early digital health companies went broke because they never figured this part out, and it’s still one of the first things investors check. Viz.ai got this right. They proved not just that their tool worked clinically, but that it had real economic value for the hospital. By showing they could cut down on hospital stays and improve patient outcomes, they could make a compelling case to payers that their tech actually lowered total healthcare costs. Getting a Category I CPT code, which is for permanent reimbursement, is a huge win and tells the market you have a viable business. Another good move for new tech is to get a Breakthrough Device Designation from the FDA, which can speed up your path to market and make you eligible for NTAP (New Technology Add-On Payment), giving hospitals an extra incentive to use your product early on.

Conclusion for Investors: Focus on Measurable Outcomes and Integrated Solutions

The data from the AI Health Investment Tracker, when you look at which companies get and keep funding, points to one thing for anyone investing in cardiovascular AI: put your money on tools that deliver real clinical results and plug into the hospital’s existing workflow. Don’t fall for the big, sweeping promises about administrative savings that can’t be backed up with a specific ROI. The money trail tells the story. The capital that flowed into Viz.ai and Tempus AI is a world apart from the cash that was set on fire at Olive AI. As an investor, you should be demanding to see:

• Rigorous Clinical Validation: Peer-reviewed data showing the tech improves patient outcomes, speeds up diagnosis, or makes treatment more effective.
• Clear Reimbursement Pathways: They either have CPT codes and payer contracts or a believable plan to get them.
• Strong Data Moats and Regulatory Acumen: A unique dataset that makes their models better, and a team that knows how to deal with the FDA, GMLP, and a proper QMS.
• Capital Efficiency: A lean plan for development and sales that’s focused on delivering value, not just burning cash on big ideas that haven’t been tested. There’s plenty of opportunity in cardiovascular AI, but it’s for companies building tools on a solid foundation of clinical proof and commercial sense, not speculative hype.

  Methodology note: These numbers come from public financial disclosures, VC databases, and bankruptcy filings. This includes the details of Tiger Global’s $100 million Series D in Viz.ai (at a $1.2 billion valuation), GV’s investment in Tempus AI (with a past reported valuation of $14 billion), and the asset liquidation records from Olive AI’s bankruptcy which detail the roughly $900 million in lost funding.